Arcutis Biotherapeutics, Inc. ARQT
Updated: 11 Jun 2026
No signal published yet
We already track Arcutis Biotherapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Arcutis Biotherapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Arcutis Biotherapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In June 2026, Arcutis announced that the FDA set a target action date of June 29, 2026, for its application to expand ZORYVE cream to treat plaque psoriasis in children aged 2 to 5. The company also reported reaching a self-sustaining financial position with positive cash flow as of June 2026.
What Firelda Watch includes for Arcutis Biotherapeutics, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Arcutis Biotherapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Arcutis Biotherapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more